Bli medlem
Bli medlem

Du är här


Bavarian Nordic A/S: Bavarian Nordic Presents Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the AACR Annual Meeting 2014

KVISTGAARD, Denmark, April 7, 2014
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated
data from an NCI sponsored combination study of Bavarian Nordic's active
immunotherapy candidate PROSTVAC and ipilimumab will be presented at the
American Association for Cancer Research (AACR) Annual Meeting in San Diego
on Wednesday, April 9, 2014. The data highlights the potential synergy of
combining PROSTVAC with an immune checkpoint inhibitor.

Promising results showing clinical evidence from this phase 1 trial combining
PROSTVAC plus ipilimumab were previously published in The Lancet Oncology.
The reported median overall survival was 34.4 months in men with metastatic
prostate cancer, and the combination therapy was well-tolerated. The
presentation at the AACR conference will show hypothesis-generating data
correlating immune outcomes with overall survival. These data provide
rationale for prospectively evaluating these potential immune correlates of
clinical benefit from combining PROSTVAC and immune checkpoint blockade in
follow-on clinical studies.

The senior author for the presentation as a poster is Jeffrey Schlom, Ph.D.,
Chief, Laboratory of Tumor Immunology and Biology, National Cancer Institute,
NIH. The presentation will take place on Wednesday, April 9, 2014 from 8:00
AM -12:00 PM PDT. An abstract entitled: "A combination trial of vaccine plus
ipilimumab in metastatic castration-resistant prostate cancer patients:
Immune correlates" is available online at

James B. Breitmeyer, President of the Cancer Immunotherapy Division of
Bavarian Nordic, said: "We are excited to continue exploration of the
potential synergy in clinical response from combination therapy with PROSTVAC
and immune checkpoint inhibitors, including ipilimumab, as well as a number
of other anticancer agents."

Asger Aamund
Chairman of the Board

Anders Hedegaard, President&CEO. Phone +45 23 20 30 64

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious
diseases. Lead product candidates are PROSTVAC®, an immunotherapy product
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox
vaccine candidate in Phase 3 development, which is being developed and
supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. The vaccine is approved in Canada under
the trade name IMVAMUNE and in the European Union under the trade name

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored
Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information,

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.